The BDX-XL2 test has shown early promise in ruling out cancer through blood samples.
A 1,048-patient study published in the Oncologist demonstrated the prognostic value of the VeriStrat test in patients with non-small cell lung cancer.
Dr. Skibo discusses how ddPCR-based liquid biopsy means that physicians do not have to wait weeks for genomic information.
Methods for measuring ctDNA, circulating tumour RNA (ctRNA), and circulating proteomic signatures from the blood are non-invasive and provide diagnostic information.
In the study, ddPCR detected PD-L1 mRNAs with a dynamic range of 32–138 copies from plasma. If validated, such a test could offer additional information to physicians.
Promising initial findings demonstrate the technical feasibility of the PD-L1 circulating blood test.
Can prognostic testing improve care for lung cancer patients and help physicians meet OCM quality measures? Dr. Ray Page discusses the topic.
Dr. Skibo discusses how ddPCR-based liquid biopsy could become an indispensable method for doctors to categorize a patient’s disease.
Article from Global Engage, interviewing Dr. Gary Pestano and Dr. Hestia Mellert about the future of droplet digital PCR.
Clinical lab products article: Blood-Based Approach to PD-L1 Detection Shows Concordance with Immunohistochemistry. Comments from Dr. Pritchett, Dr. Niu